ArticleCureus2025
Association Between Body Mass Index and Hematotoxicity in Gynecological Cancer Patients Receiving Paclitaxel-Carboplatin Therapy: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn gynecological cancer treatment, carboplatin dosage is generally calculated based on renal function to ensure appropriate drug exposure. In clinical practice, serum creatinine levels are sometimes adjusted when extremely low values are observed to avoid overdosing. Body mass index (BMI) has been suspected to influence the development of chemotherapy-induced hematotoxicity, but this relationship remains uncertain. This study aimed to investigate the effect of BMI on hematotoxicity in gynecological cancer patients receiving paclitaxel-carboplatin combination therapy (TC therapy).
methodsUsing electronic medical records, patients with gynecological cancer who received TC therapy for the first time between January 2014 and December 2021 were included in this retrospective study. BMI, Cockcroft-Gault formula (C-G formula) factors such as age, body weight, serum creatinine (sCr), and laboratory values related to hematotoxicity (leukopenia, anemia, neutropenia, and thrombocytopenia) prior to and after TC therapy. Nadir values obtained before the start of the second course of TC therapy were extracted from the electronic medical records. Among the extracted patient information, the presence or absence of grade ≥ 3 hematotoxicity was used as the outcome variable, and the grade of each blood cell prior to TC therapy, age, glomerular filtration rate (GFR) calculated using the C-G formula, and BMI were used as explanatory variables in multiple logistic regression analysis.
resultsAmong the 273 eligible patients, no significant correlation was found between grade ≥ 3 hematotoxicity and BMI (leukopenia: odds ratio (OR) = 1.08, 95% confidence interval (CI) = 0.98-1.19, p = 0.12; anemia: OR = 1.06, 95% CI = 0.85-1.30, p = 0.57; neutropenia: OR = 1.05, 95% CI = 0.97-1.15, p = 0.20; thrombocytopenia: OR = 1.34, 95% CI = 0.93-1.89, p = 0.10). Younger age was associated with an increased risk of grade ≥ 3 leukopenia (OR = 0.96, 95% CI = 0.92-1.00, P = 0.035), and lower GFR was associated with increased risks of grade ≥ 3 leukopenia (OR = 0.97, 95% CI = 0.95-1.00, P = 0.049) and anemia (OR = 0.95, 95% CI = 0.89-0.99, P < 0.01).
conclusionsBMI was not associated with grade ≥ 3 hematotoxicity across all hematologic endpoints. Although serum creatinine correction to 0.7 mg/dL may reduce BMI-related variability in renal function estimation, this interpretation remains speculative because our study did not include a non-corrected comparison group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.